Unnati Pharmax

Nindanib Nintedanib 150mg Capsules
Composition: Nintedanib 150mg Capsules
International Trade Name: Ofev®

Nindanib 150mg is a high-quality Nintedanib capsule formulation, a potent triple angiokinase inhibitor widely recognized under the international brand name Ofev®. Manufactured in WHO-GMP certified facilities, Nindanib is supplied by trusted pharmaceutical exporters from India to support advanced global treatment programs for fibrotic lung diseases and oncology indications.

Nintedanib works by inhibiting multiple tyrosine kinases, including VEGFR, FGFR, and PDGFR, thereby reducing fibroblast proliferation, angiogenesis, and disease progression. Nindanib 150mg Capsules are primarily indicated for the treatment of idiopathic pulmonary fibrosis (IPF) to slow disease progression and for select indications in oncology, including certain non-small cell lung cancers (NSCLC) in combination therapy.

Nindanib 150mg Capsules are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for pulmonology clinics, oncology centers, tertiary care hospitals, and international pharmaceutical distributors.

Nintib 100 Soft Gelatin Capsules
Composition: Nintedanib 100 mg per capsule
International Trade Name: Ofev®

Nintib 100 is a high-quality Nintedanib soft gelatin capsule, a biosimilar equivalent of the internationally recognized antifibrotic and tyrosine kinase inhibitor Ofev®. Manufactured in WHO-GMP certified facilities, Nintib is supplied by trusted pharmaceutical exporters from India to support advanced global pulmonary and oncology treatment programs.

Nintedanib is a triple angiokinase inhibitor that targets vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors. By inhibiting these pathways, Nintib slows disease progression in conditions characterized by abnormal tissue fibrosis and angiogenesis.

Nintib 100 mg Soft Gelatin Capsules are primarily indicated for the treatment of idiopathic pulmonary fibrosis (IPF), chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, and as an adjunct therapy in certain solid tumors, as prescribed by a healthcare professional.

Nintib 100 Soft Gelatin Capsules are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, pulmonology and oncology clinics, government health programs, and international pharmaceutical distributors.

Nindalieva 150 mg Capsules
Composition: Nintedanib 150 mg per capsule
International Trade Name: Ofev®

Nindalieva 150 mg is a high-quality Nintedanib capsule, a biosimilar equivalent of the internationally recognized antifibrotic and tyrosine kinase inhibitor Ofev®. Manufactured in WHO-GMP certified facilities, Nindalieva is supplied by trusted pharmaceutical exporters from India to support advanced global pulmonary and oncology treatment programs.

Nintedanib is a triple angiokinase inhibitor that targets vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors. By inhibiting these pathways, Nindalieva slows disease progression in conditions characterized by abnormal tissue fibrosis and angiogenesis.

Nindalieva 150 mg Capsules are primarily indicated for the treatment of idiopathic pulmonary fibrosis (IPF), chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, and as an adjunct therapy in certain solid tumors, as prescribed by a healthcare professional.

Nindalieva 150 mg Capsules are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, pulmonology and oncology clinics, government health programs, and international pharmaceutical distributors.

Nintib (Nintedanib) 150 mg, also marketed under the brand name Ofev, is a prescription medication primarily used in the management of idiopathic pulmonary fibrosis (IPF) and other serious, progressive lung diseases. It belongs to a class of drugs known as tyrosine kinase inhibitors, which work by blocking specific pathways involved in inflammation, fibrosis, and abnormal tissue remodeling in the lungs. By targeting these pathways, Nintib helps slow the progression of lung damage rather than curing the disease.

What is Nintedanib used for?

Nintedanib 150 mg is most commonly prescribed for:

• Idiopathic Pulmonary Fibrosis (IPF) – a chronic, progressive lung disease characterized by scarring (fibrosis) of lung tissue, leading to worsening shortness of breath and reduced oxygen exchange.

• Chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, including autoimmune-related ILDs.

• Systemic sclerosis–associated interstitial lung disease (SSc-ILD), where fibrosis affects lung function in patients with systemic sclerosis.

Clinical studies have shown that Nintedanib can significantly reduce the rate of decline in forced vital capacity (FVC), a key measure of lung function. While it does not reverse existing fibrosis, slowing disease progression can help preserve quality of life and functional capacity for a longer period.

How Nintib works

Nintedanib is a multi-targeted tyrosine kinase inhibitor. It blocks receptors involved in fibrotic processes, including:

• Vascular endothelial growth factor (VEGF) receptors

• Fibroblast growth factor (FGF) receptors

• Platelet-derived growth factor (PDGF) receptors

These receptors play a role in fibroblast activation and collagen deposition, which contribute to lung scarring. By inhibiting these signaling pathways, Nintib reduces ongoing fibrotic activity in lung tissue.

Dosage and administration

The standard recommended dose is 150 mg taken orally twice daily, approximately 12 hours apart, preferably with food to improve tolerability. Capsules should be swallowed whole with water and should not be crushed or chewed.

Dose adjustments or temporary interruptions may be necessary if side effects occur, especially gastrointestinal symptoms or liver enzyme elevations. In some cases, the dose may be reduced to 100 mg twice daily based on individual tolerance and physician guidance.

Laboratory abnormalities, particularly elevated liver enzymes, can occur, which is why regular liver function monitoring is required before and during treatment. Less commonly, patients may experience bleeding events, hypertension, or cardiovascular issues.

Patients with liver disease, bleeding disorders, or those taking anticoagulants should use Nintedanib with caution and under strict medical supervision.

Drug interactions and precautions

Nintedanib may interact with certain medications, including:

• Anticoagulants (blood thinners)

• Strong CYP enzyme inhibitors or inducers

• Certain antifungal or antibiotic medications

It is important for patients to inform their healthcare provider about all medications, supplements, and herbal products they are taking before starting therapy.

Nintib is not recommended during pregnancy, as it may harm an unborn baby. Effective contraception is advised for women of childbearing potential during treatment.

Alkros One Crizotinib Capsules 250mg
Composition: Crizotinib 250mg Capsules
International Trade Name: Xalkori®

Alkros One 250mg is a high-quality Crizotinib capsule formulation, a potent and selective tyrosine kinase inhibitor (TKI) widely recognized under the international brand name Xalkori®. Manufactured in WHO-GMP certified facilities, Alkros One is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in non-small cell lung cancer (NSCLC) with ALK or ROS1 gene rearrangements.

Crizotinib works by selectively inhibiting ALK (anaplastic lymphoma kinase) and ROS1 tyrosine kinases, blocking downstream signaling pathways involved in cancer cell proliferation and survival. Alkros One 250mg Capsules are primarily indicated for the treatment of patients with locally advanced or metastatic NSCLC harboring ALK or ROS1-positive genetic alterations.

Alkros One Crizotinib 250mg Capsules are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

 

Erlonat 150 Tablets
Composition: Erlotinib 150 mg per tablet
International Trade Name: Tarceva®

Erlonat 150 mg is a high-quality Erlotinib tablet, a biosimilar equivalent of the internationally recognized targeted therapy Tarceva®. Manufactured in WHO-GMP certified facilities, Erlonat is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly for patients with non-small cell lung cancer (NSCLC) and pancreatic cancer.

Erlotinib is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that blocks EGFR-mediated signaling pathways. By inhibiting EGFR activation, Erlonat suppresses tumor cell proliferation, induces apoptosis, and reduces metastasis, making it an effective therapy for EGFR mutation-positive cancers.

Erlonat 150 mg Tablets are primarily indicated for the treatment of metastatic or locally advanced NSCLC with EGFR-activating mutations and for pancreatic cancer in combination with gemcitabine, as prescribed by an oncologist.

Erlonat 150 mg Tablets are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, hospitals, government cancer programs, and international pharmaceutical distributors.

 

AFANAT 30 mg Tablets
Composition: Afatinib Dimaleate 30 mg per tablet
International Trade Name: Gilotrif®

AFANAT 30 mg is a high-quality Afatinib Dimaleate tablet, a biosimilar equivalent of the internationally recognized targeted therapy Gilotrif®. Manufactured in WHO-GMP certified facilities, AFANAT is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations.

Afatinib is an irreversible tyrosine kinase inhibitor (TKI) that selectively blocks signaling from the epidermal growth factor receptor (EGFR) family, including EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4). By inhibiting these pathways, AFANAT helps prevent tumor cell proliferation, survival, and metastasis, making it an effective therapy for EGFR mutation-positive NSCLC.

AFANAT 30 mg Tablets are primarily indicated for the first-line treatment of patients with metastatic NSCLC whose tumors have non-resistant EGFR mutations, as prescribed by an oncologist.

AFANAT 30 mg Tablets are manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology centers, hospitals, government cancer programs, and international pharmaceutical distributors.

TISHTHA 100 MGComposition: NIVOLUMAB  100mgInternational Trade Name: OPDIVO/OPDYTA ®

Nivolumab Tishtha 100 mg (Opdivo/Opdyta) is an advanced immunotherapy injection used in the treatment of various cancers. It contains Nivolumab 100 mg, a monoclonal antibody that works by strengthening the body’s immune system to recognize and attack cancer cells. The reference brand Opdivo, developed by Bristol Myers Squibb, is globally recognized for its role in modern cancer immunotherapy. Nivolumab Tishtha and Opdyta provide effective and quality-assured alternatives, offering the same active ingredient for oncology treatment under strict pharmaceutical standards.
Nivolumab belongs to a class of medicines known as immune checkpoint inhibitors. It targets the PD-1 (programmed death-1) receptor on immune cells and blocks signals that prevent the immune system from attacking tumors. By inhibiting this pathway, the medicine enhances the body’s natural immune response against cancer. This innovative mechanism has significantly improved outcomes in patients with several advanced malignancies and is considered a breakthrough in targeted cancer therapy.
Nivolumab Tishtha 100 mg is indicated for the treatment of multiple cancers, including non-small cell lung cancer, melanoma, kidney cancer (renal cell carcinoma), head and neck cancer, classical Hodgkin lymphoma, and certain gastrointestinal cancers, as prescribed by an oncologist. It is administered as an intravenous infusion in a hospital or oncology clinic by trained healthcare professionals. The dosage and treatment schedule depend on the patient’s condition, body weight, and response to therapy. Regular monitoring is required to assess effectiveness and manage any side effects.
During treatment, patients undergo routine blood tests and clinical evaluations to monitor organ function and immune-related reactions. Because Nivolumab stimulates the immune system, it may sometimes cause the immune system to attack normal organs and tissues. Possible side effects include fatigue, skin rash, diarrhea, cough, shortness of breath, or inflammation of organs such as the lungs, liver, or thyroid. Early detection and prompt medical management are essential to prevent serious complications. Patients should immediately report unusual symptoms to their healthcare provider.
Safety precautions are important when using Nivolumab Tishtha. The medicine is not recommended during pregnancy or breastfeeding, as it may pose risks to the fetus or infant. Effective contraception is advised during treatment and for a period after the last dose. Patients with autoimmune diseases or organ transplants should inform their doctor before starting therapy. Only qualified healthcare professionals should prepare and administer the injection, following strict clinical safety protocols.
Nivolumab Tishtha 100 mg is supplied in a sterile vial for intravenous infusion and must be stored under recommended refrigerated conditions to preserve stability. Its manufacturing follows international quality and safety standards, ensuring consistent potency and reliability in cancer care. As part of a comprehensive oncology treatment plan, this immunotherapy is often combined with supportive care and regular follow-up to optimize patient outcomes.
With its innovative immune-enhancing action, Nivolumab Tishtha represents a significant advancement in cancer treatment. When administered under expert medical supervision, it can help control disease progression and improve survival in eligible patients. Strict adherence to the prescribed treatment schedule and continuous communication with healthcare providers are essential for achieving the safest and most effective therapeutic results.

Afatinib 40 mg tablets are a targeted anti-cancer medication used in the treatment of specific types of non-small cell lung cancer (NSCLC). This medicine belongs to the class of tyrosine kinase inhibitors (TKIs) and works by blocking the activity of certain proteins that promote the growth and spread of cancer cells.

Formulated with precision, Afatinib helps slow down or stop the progression of cancer, improving patient outcomes when prescribed by a healthcare professional.

Key Features:

• Contains Afatinib 40 mg as the active ingredient
• Used for treatment of metastatic non-small cell lung cancer (NSCLC)
• Works by inhibiting epidermal growth factor receptor (EGFR) pathways
• High efficacy in targeted cancer therapy
• Oral administration for patient convenience

Product Details:

• Dosage Form: Tablet
• Strength: 40 mg
• Packaging Type: As per requirement / standard packing
• Prescription Required: Yes
• Storage: Store in a cool, dry place away from direct sunlight

Applications:

• Widely used in oncology treatments
• Recommended for patients with EGFR mutation-positive lung cancer

Safety Information:

• To be used strictly under medical supervision
• Not recommended for self-medication
• Keep out of reach of children

We offer quality-assured Afatinib 40 mg tablets sourced from reliable manufacturers, ensuring safety, efficacy, and timely delivery to our clients.

Product Name: Afanat 20mg Tablet
Generic Name: Afatinib Dimaleate 20mg
Manufacturer: Natco Pharma Ltd
Dosage Form: Tablet

Product Description:
Afanat 20mg Tablet is an anti-cancer medication used in the treatment of non-small cell lung cancer (NSCLC) in adult patients with specific EGFR (epidermal growth factor receptor) mutations. It belongs to a class of medicines known as tyrosine kinase inhibitors.

This medicine works by blocking the activity of certain proteins (EGFR, HER2, HER4) that promote the growth and spread of cancer cells, thereby helping to slow down or stop tumor progression.

Afanat 20mg Tablet is usually taken on an empty stomach, preferably at the same time each day, as prescribed by a healthcare professional. It is a potent medication and should only be used under medical supervision.

Key Features:

• Effective targeted therapy for NSCLC
• Contains Afatinib 20mg
• Helps inhibit cancer cell growth
• Oral tablet for convenient administration

Indications:

• Non-small cell lung cancer (EGFR mutation positive)

Common Side Effects:

• Diarrhea
• Skin rash
• Dry skin
• Nausea & vomiting
• Loss of appetite

Storage: Store below 30°C in a dry place

Note: Use strictly under doctor’s prescription.

Pemetero 500 Pemetrexed Injection
Composition: Pemetrexed 500 mg per vial
International Trade Name: Alimta®

Pemetero 500 is a high-quality Pemetrexed injection, a biosimilar equivalent of the internationally recognized chemotherapeutic agent Alimta®. Manufactured in WHO-GMP certified facilities, Pemetero is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Pemetrexed is an antifolate chemotherapeutic agent that inhibits multiple folate-dependent enzymes involved in the synthesis of DNA and RNA, thereby preventing cancer cell proliferation and inducing apoptosis. Pemetero is particularly effective in rapidly dividing tumor cells.

Pemetero 500 Injection is primarily indicated for the treatment of malignant pleural mesothelioma and non-small cell lung cancer (NSCLC), either as monotherapy or in combination regimens, as prescribed by an oncologist.

Pemetero 500 Pemetrexed Injection is manufactured under stringent GMP standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, export-grade vials with complete regulatory documentation, making it suitable for oncology centers, hospitals, government cancer programs, and international pharmaceutical distributors.

Afanat 30mg Tablet is a targeted anti-cancer medication used in the treatment of non-small cell lung cancer (NSCLC) in adult patients with specific EGFR (epidermal growth factor receptor) mutations. It belongs to the class of tyrosine kinase inhibitors (TKIs).

This medicine works by inhibiting the activity of proteins such as EGFR, HER2, and HER4 that are responsible for the growth and spread of cancer cells. By blocking these pathways, Afanat 30mg helps slow down or stop tumor progression.

Afanat 30mg Tablet should be taken on an empty stomach, preferably at the same time each day, as directed by a healthcare professional. It is a potent medication and must be used strictly under medical supervision.

Key Features:

• Targeted therapy for EGFR mutation-positive NSCLC
• Contains Afatinib 30mg
• Helps inhibit cancer cell growth and spread
• Convenient oral dosage form

Indications:

• Non-small cell lung cancer (NSCLC)

Common Side Effects:

• Diarrhea
• Skin rash
• Dry skin
• Nausea and vomiting
• Loss of appetite
• Mouth inflammation (stomatitis)

Storage: Store below 30°C in a dry place

Note: To be used only under medical prescription.

PEMETYRA Pemetrexed Injection IP 500mg
Composition: Pemetrexed 500mg / Vial Injection
International Trade Name: Alimta®

PEMETYRA 500mg is a high-quality Pemetrexed injectable formulation, an antifolate chemotherapeutic agent widely recognized under the international brand name Alimta®. Manufactured in WHO-GMP certified facilities, PEMETYRA Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Pemetrexed works by inhibiting multiple folate-dependent enzymes involved in nucleotide synthesis, leading to disruption of DNA and RNA synthesis and inducing apoptosis in rapidly dividing cancer cells. PEMETYRA 500mg Injection is primarily indicated for the treatment of malignant pleural mesothelioma and non-small cell lung cancer (NSCLC), either as monotherapy or in combination with platinum-based chemotherapeutic agents.

PEMETYRA Pemetrexed Injection 500mg is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Posid 100mg Etoposide Injection
Composition: Etoposide 100mg / Vial Injection
International Trade Name: Vepesid®

Posid 100mg is a high-quality Etoposide injectable formulation, a semisynthetic podophyllotoxin derivative widely recognized under the international brand name Vepesid®. Manufactured in WHO-GMP certified facilities, Posid Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Etoposide works by inhibiting topoisomerase II, an enzyme responsible for DNA unwinding during replication, leading to DNA strand breaks and apoptosis in rapidly dividing cancer cells. Posid 100mg Injection is primarily indicated for the treatment of small cell lung cancer, testicular cancer, lymphomas, and other solid tumors, either as monotherapy or in combination chemotherapy regimens.

Posid 100mg Etoposide Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Pexate 500 Pemetrexed Injection
Composition: Pemetrexed 500mg / Vial Injection
International Trade Name: Alimta®

Pexate 500 is a high-quality Pemetrexed injectable formulation, an antifolate chemotherapeutic agent widely recognized under the international brand name Alimta®. Manufactured in WHO-GMP certified facilities, Pexate Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Pemetrexed works by inhibiting multiple folate-dependent enzymes involved in the synthesis of DNA and RNA, leading to disruption of cell proliferation and induction of apoptosis in rapidly dividing cancer cells. Pexate 500 Injection is primarily indicated for the treatment of malignant pleural mesothelioma and non-small cell lung cancer (NSCLC), either as monotherapy or in combination with platinum-based chemotherapy agents.

Pexate 500 Pemetrexed Injection is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.